 SUZHOU, China and PALO ALTO, Calif. , May 19, 2021 PRNewswire -- Gracell Biotechnologies Inc. NASDAQ: GRCL Gracell, a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, is presenting updated results of their first-in-human multicenter study of GC012F for the treatment of relapsed andor refractory multiple myeloma, a FasTCAR-enabled BCMACD19 dual-targeting CAR-T cell therapy currently in development for the treatment of multiple myeloma, at the 2021 American Society of Clinical Oncology ASCO Annual Meeting and the European Hematology Association 2021 EHA2021 Congress. 